Drug Approval | December 28, 2021
Dr Reddy’s receives Emergency Use Authorisation for molnupiravir
The company will market it under the brand name Molflu
The company will market it under the brand name Molflu
The company has developed the API in house at its R&D center in Hyderabad
It plans to deliver over 300 million doses to the Indian government
The drug will be marketed under the brand name Molnaflu
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
This product will be manufactured at Lupin's Goa facility in India
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
The Home Healthcare market is expected to be US $ 14.2 by 2025
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Flattish volume growth and subdued new launches were key factors for last month
Subscribe To Our Newsletter & Stay Updated
